Beneficial Ownership Report · SCHEDULE 13G
Inovio Pharmaceuticals, Inc.
INONASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Inovio Pharmaceuticals Inc.
- Company CIK
- 0001055726
- Street
- 660 West Germantown Pike
- Street (continued)
- Suite 110
- City
- Plymouth Meeting
- State / country code
- PA
- Postal code
- 19462
Statement details
- Security class
- Common Stock, par value $0.001 per share
- Event date
- 11/06/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- TANG CAPITAL MANAGEMENT, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Aggregate amount owned
- 17,978,200.00
- Percent of class
- 9.99
- Sole voting power
- 0.00
- Shared voting power
- 17,978,200.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 17,978,200.00
- Aggregate excludes certain shares
- N
- Comments
- Tang Capital Management, LLC ("TCM") beneficially owns 17,978,200 shares of the Issuer's Common Stock, which consists of: (i) 17,659,259 shares of the Issuer's Common Stock and (ii) 318,941 shares currently issuable upon exercise of pre-funded warrants (the "Warrants," as defined in the Issuer's Registration Statement filed on Form 424(b)(5) with the Securities and Exchange Commission on November 6, 2026). TCM beneficially owns 10,150,264 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. The percentages used herein are based on 179,961,968 shares of Common Stock outstanding which is comprised of: (i) 179,643,027 shares of Common Stock outstanding as of November 6, 2026 as set forth in the Issuer's Prospectus filed on Form 424(b)(5) that was filed with the Securities and Exchange Commission on November 6, 2026, and (ii) 318,941 shares currently issuable upon exercise of Warrants. TCM shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc. ("TCP III"), Tang Capital Partners IV, Inc. ("TCP IV") and Kevin Tang.
Reporting person 2
- Name
- KEVIN TANG
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 17,978,200.00
- Percent of class
- 9.99
- Sole voting power
- 0.00
- Shared voting power
- 17,978,200.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 17,978,200.00
- Aggregate excludes certain shares
- N
- Comments
- Kevin Tang beneficially owns 17,978,200 shares of the Issuer's Common Stock, which consists of: (i) 17,659,259 shares of the Issuer's Common Stock and (ii) 318,941 shares currently issuable upon exercise of Warrants. Kevin Tang beneficially owns 10,150,264 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III, TCP IV, and TCM.
Reporting person 3
- Name
- TANG CAPITAL PARTNERS, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 4,008,311.00
- Percent of class
- 2.23
- Sole voting power
- 0.00
- Shared voting power
- 4,008,311.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 4,008,311.00
- Aggregate excludes certain shares
- N
- Comments
- TCP beneficially owns 4,008,311 shares of the Issuer's Common Stock, which consists of: (i) 3,937,202 shares of the Issuer's Common Stock and (ii) 71,109 shares currently issuable upon exercise of Warrants. TCP beneficially owns 2,263,042 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. TCP may not exercise any portion of the Warrants for shares of Common Stock if, as a result of the exercise, TCP, together with its affiliates and any other person or entity acting as a group, would own more than 9.99% of the Issuer's outstanding shares of Common Stock after exercise. However, TCP may increase such percentage to any other percentage, not in excess of 19.99% (to the extent such limit is required under applicable Nasdaq rules), by providing written notice to the Issuer, provided that any increase in such percentage shall not be effective until 61 days after notice is provided to the Issuer. The foregoing limitations remain in effect with respect to the Warrants, and, accordingly, only 71,109 shares are currently issuable upon exercise of the Warrants. TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.
Reporting person 4
- Name
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 5,953,267.00
- Percent of class
- 3.30
- Sole voting power
- 0.00
- Shared voting power
- 5,953,267.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 5,953,267.00
- Aggregate excludes certain shares
- N
- Comments
- TCPI beneficially owns 5,953,267 shares of the Issuer's Common Stock, which consists of: (i) 5,847,653 shares of the Issuer's Common Stock and (ii) 105,614 shares currently issuable upon exercise of Warrants. TCPI beneficially owns 3,361,138 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. Based on the ownership limitations described above, only 105,614 shares are currently issuable upon exercise of the Warrants. TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.
Reporting person 5
- Name
- TANG CAPITAL PARTNERS III, INC
- Citizenship / organization
- NV
- Reporting person type
- CO
- Aggregate amount owned
- 4,008,311.00
- Percent of class
- 2.23
- Sole voting power
- 0.00
- Shared voting power
- 4,008,311.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 4,008,311.00
- Aggregate excludes certain shares
- N
- Comments
- TCP III beneficially owns 4,008,311 shares of the Issuer's Common Stock, which consists of: (i) 3,937,202 shares of the Issuer's Common Stock and (ii) 71,109 shares currently issuable upon exercise of Warrants. TCP III beneficially owns 2,263,042 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. Based on the ownership limitations described above, only 71,109 shares are currently issuable upon exercise of the Warrants. TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang.
Reporting person 6
- Name
- TANG CAPITAL PARTNERS IV, INC
- Citizenship / organization
- NV
- Reporting person type
- CO
- Aggregate amount owned
- 4,008,311.00
- Percent of class
- 2.23
- Sole voting power
- 0.00
- Shared voting power
- 4,008,311.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 4,008,311.00
- Aggregate excludes certain shares
- N
- Comments
- TCP IV beneficially owns 4,008,311 shares of the Issuer's Common Stock, which consists of: (i) 3,937,202 shares of the Issuer's Common Stock and (ii) 71,109 shares currently issuable upon exercise of Warrants. TCP IV beneficially owns 2,263,042 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. Based on the ownership limitations described above, only 71,109 shares are currently issuable upon exercise of the Warrants. TCP IV shares voting and dispositive power over such shares with TCM and Kevin Tang.
Item 1
Issuer
Inovio Pharmaceuticals Inc.
Principal executive office address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, 19462
Item 2
Citizenship
TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI are Delaware limited partnerships. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.
Filing person
This Statement on Schedule 13G (this "Statement") is filed by TCM, the general partner of TCP and TCPI; Kevin Tang, the manager of TCM and Chief Executive Officer of TCP III and TCP IV; TCP; TCPI; TCP III; and TCP IV.
Principal business or residence address
The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
Item 3
Not applicable indication
Y
Item 4
Percent of class
9.99
Amount beneficially owned
17,978,200
Sole voting power
0 shares
Shared voting power
17,978,200 shares
Sole dispositive power
0 shares
Shared dispositive power
17,978,200 shares
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 99.1
Signature 1
- Reporting person
- TANG CAPITAL MANAGEMENT, LLC
- Signed
- /s/ Kevin Tang
- Title
- Manager
- Date
- 11/16/2026
Signature 2
- Reporting person
- KEVIN TANG
- Signed
- /s/ Kevin Tang
- Title
- Self
- Date
- 11/16/2026
Signature 3
- Reporting person
- TANG CAPITAL PARTNERS, LP
- Signed
- /s/ Kevin Tang
- Title
- Manager, Tang Capital Management, LLC, General Partner
- Date
- 11/16/2026
Signature 4
- Reporting person
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
- Signed
- /s/ Kevin Tang
- Title
- Manager, Tang Capital Management, LLC, General Partner
- Date
- 11/16/2026
Signature 5
- Reporting person
- TANG CAPITAL PARTNERS III, INC
- Signed
- /s/ Kevin Tang
- Title
- Chief Executive Officer
- Date
- 11/16/2026
Signature 6
- Reporting person
- TANG CAPITAL PARTNERS IV, INC
- Signed
- /s/ Kevin Tang
- Title
- Chief Executive Officer
- Date
- 11/16/2026
Filed exhibits
- EXHIBIT 99.1 ↗ex99_1.htm
Company context
INOVIO’s DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO’s proprietary medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that enable the body’s cells to produce specific proteins to target and fight disease. INOVIO’s proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body’s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 17, 2026
- SCHEDULE 13G/A - filed by HIGHBRIDGE CAPITAL MANAGEMENT LLC regarding INOVIO PHARMACEUTICALS, INC.Nov 16, 2026
- Results of Operations and Financial ConditionNov 10, 2026
- 10-Q filingNov 10, 2026
- Entry into a Material Definitive Agreement · Regulation FD Disclosure · Other EventsNov 9, 2026